REFERENCES
Aklillu, E., Zumla, A., Habtewold, A., Amogne, W., Makonnen, E., Yimer, G., et al. (2020). Early or deferred initiation of efavirenz during rifampicin-based TB therapy has no significant effect on CYP3A induction in TB-HIV infected patients. Br. J. Pharmacol. n/a :
Alexander, S.P.H., Christopoulos, A., Davenport, A.P., Kelly, E., Mathie, A., Peters, J.A., et al. (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. Br. J. Pharmacol.176 : S21–S141.
Alonso, A., Marsal, S., and Julià, A. (2015). Analytical Methods in Untargeted Metabolomics: State of the Art in 2015. Front. Bioeng. Biotechnol. 3 :.
Beger, R.D., Dunn, W., Schmidt, M.A., Gross, S.S., Kirwan, J.A., Cascante, M., et al. (2016). Metabolomics enables precision medicine: ‘A White Paper, Community Perspective’. Metabolomics Off. J. Metabolomic Soc. 12 : 149.
Blaženović, I., Kind, T., Ji, J., and Fiehn, O. (2018). Software Tools and Approaches for Compound Identification of LC-MS/MS Data in Metabolomics. Metabolites 8 : 31.
Crews, K.R., Gaedigk, A., Dunnenberger, H.M., Leeder, J.S., Klein, T.E., Caudle, K.E., et al. (2014). Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin. Pharmacol. Ther. 95 : 376–382.
Curtis, M.J., Alexander, S., Cirino, G., Docherty, J.R., George, C.H., Giembycz, M.A., et al. (2018). Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers. Br. J. Pharmacol. 175 : 987–993.
Daali, Y., Cherkaoui, S., Doffey-Lazeyras, F., Dayer, P., and Desmeules, J.A. (2008). Development and validation of a chemical hydrolysis method for dextromethorphan and dextrophan determination in urine samples: Application to the assessment of CYP2D6 activity in fibromyalgia patients. J. Chromatogr. B 861 : 56–63.
Dias, D.A., Jones, O.A.H., Beale, D.J., Boughton, B.A., Benheim, D., Kouremenos, K.A., et al. (2016). Current and Future Perspectives on the Structural Identification of Small Molecules in Biological Systems. Metabolites 6 : 46.
Dührkop, K., Fleischauer, M., Ludwig, M., Aksenov, A.A., Melnik, A.V., Meusel, M., et al. (2019). SIRIUS 4: a rapid tool for turning tandem mass spectra into metabolite structure information. Nat. Methods16 : 299–302.
Elens, L., Bouamar, R., Hesselink, D.A., Haufroid, V., Heiden, I.P. van der, Gelder, T. van, et al. (2011). A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin. Chem. 57 : 1574–1583.
Farrell, E.K., and Merkler, D.J. (2008). Biosynthesis, degradation, and pharmacological importance of the fatty acid amides. Drug Discov. Today13 : 558–568.
Forchelet, D., Béguin, S., Sajic, T., Bararpour, N., Pataky, Z., Frias, M., et al. (2018). Separation of blood microsamples by exploiting sedimentation at the microscale. Sci. Rep. 8 : 14101.
Gaedigk, A. (2013). Complexities of CYP2D6 gene analysis and interpretation. Int. Rev. Psychiatry Abingdon Engl. 25 : 534–553.
Gaedigk, A., Dinh, J.C., Jeong, H., Prasad, B., and Leeder, J.S. (2018). Ten Years’ Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics. J. Pers. Med. 8 : 15.
Gaedigk, A., Simon, S.D., Pearce, R.E., Bradford, L.D., Kennedy, M.J., and Leeder, J.S. (2008). The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83 : 234–242.
Harding, S.D., Sharman, J.L., Faccenda, E., Southan, C., Pawson, A.J., Ireland, S., et al. (2018). The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucleic Acids Res. 46 : D1091–D1106.
Hicks, J., Bishop, J., Sangkuhl, K., Müller, D., Ji, Y., Leckband, S., et al. (2015). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin. Pharmacol. Ther.98 : 127–134.
Ingelman-Sundberg, M. (2005). Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5 : 6–13.
Ivanisevic, J., and Thomas, A. (2018). Metabolomics as a Tool to Understand Pathophysiological Processes. Methods Mol. Biol. Clifton NJ1730 : 3–28.
Jensen, B.C., Parry, T.L., Huang, W., Beak, J.Y., Ilaiwy, A., Bain, J.R., et al. (2017). Effects of the kinase inhibitor sorafenib on heart, muscle, liver and plasma metabolism in vivo using non-targeted metabolomics analysis. Br. J. Pharmacol. 174 : 4797–4811.
Kaddurah-Daouk, R., Weinshilboum, R.M., and Pharmacometabolomics Research Network (2014). Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. Clin. Pharmacol. Ther. 95 : 154–167.
Karnes, J.H., Rettie, A.E., Somogyi, A.A., Huddart, R., Fohner, A.E., Formea, C.M., et al. (2020). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin. Pharmacol. Ther. n/a :
Kim, B., Lee, J., Shin, K.-H., Lee, S., Yu, K.-S., Jang, I.-J., et al. (2018). Identification of ω- or (ω-1)-Hydroxylated Medium-Chain Acylcarnitines as Novel Urinary Biomarkers for CYP3A Activity. Clin. Pharmacol. Ther. 103 : 879–887.
Kohler, I., Hankemeier, T., Graaf, P.H. van der, Knibbe, C.A.J., and Hasselt, J.G.C. van (2017). Integrating clinical metabolomics-based biomarker discovery and clinical pharmacology to enable precision medicine. Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci. 109S : S15–S21.
Kowalczuk, L., Matet, A., Dor, M., Bararpour, N., Daruich, A., Dirani, A., et al. (2018). Proteome and Metabolome of Subretinal Fluid in Central Serous Chorioretinopathy and Rhegmatogenous Retinal Detachment: A Pilot Case Study. Transl. Vis. Sci. Technol. 7 : 3.
Langaee, T., Hamadeh, I., Chapman, A.B., Gums, J.G., and Johnson, J.A. (2015). A Novel Simple Method for Determining CYP2D6 Gene Copy Number and Identifying Allele(s) with Duplication/Multiplication. PLOS ONE10 : e0113808.
Lee, C. (1995). Urinary 6βP-hydroxycortisol in humans: Analysis, biological variations, and reference ranges. Clin. Biochem. 28 : 49–54.
Lima, J.J., Thomas, C.D., Barbarino, J., Desta, Z., Van Driest, S.L., El Rouby, N., et al. (2020). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin. Pharmacol. Ther.
Magliocco, G., and Daali, Y. (2020). Modern approaches for the phenotyping of cytochrome P450 enzymes in children. Expert Rev. Clin. Pharmacol. 0 : 1–4.
Magliocco, G., Thomas, A., Desmeules, J., and Daali, Y. (2019). Phenotyping of Human CYP450 Enzymes by Endobiotics: Current Knowledge and Methodological Approaches. Clin. Pharmacokinet. 58 : 1373–1391.
Mao, J., Martin, I., McLeod, J., Nolan, G., Horn, R. van, Vourvahis, M., et al. (2017). Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A. Drug Metab. Rev. 49 : 18–34.
Nofziger, C., Turner, A.J., Sangkuhl, K., Whirl-Carrillo, M., Agúndez, J.A.G., Black, J.L., et al. (2020). PharmVar GeneFocus: CYP2D6. Clin. Pharmacol. Ther. 107 : 154–170.
Pang, H., Jia, W., and Hu, Z. (2019). Emerging Applications of Metabolomics in Clinical Pharmacology. Clin. Pharmacol. Ther.106 : 544–556.
Peñas-LLedó, E.M., and LLerena, A. (2014). CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials. Br. J. Clin. Pharmacol. 77 : 673–683.
Samer, C.F., Lorenzini, K.I., Rollason, V., Daali, Y., and Desmeules, J.A. (2013). Applications of CYP450 testing in the clinical setting. Mol. Diagn. Ther. 17 : 165–184.
Schmidt, L., Müller, J., and Göen, T. (2013). Simultaneous monitoring of seven phenolic metabolites of endocrine disrupting compounds (EDC) in human urine using gas chromatography with tandem mass spectrometry. Anal. Bioanal. Chem. 405 : 2019–2029.
Schrimpe-Rutledge, A.C., Codreanu, S.G., Sherrod, S.D., and McLean, J.A. (2016). Untargeted Metabolomics Strategies-Challenges and Emerging Directions. J. Am. Soc. Mass Spectrom. 27 : 1897–1905.
Shah, R.R., Gaedigk, A., LLerena, A., Eichelbaum, M., Stingl, J., and Smith, R.L. (2016). CYP450 genotype and pharmacogenetic association studies: a critical appraisal. Pharmacogenomics 17 : 259–275.
Snider, N.T., Sikora, M.J., Sridar, C., Feuerstein, T.J., Rae, J.M., and Hollenberg, P.F. (2008). The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6. J. Pharmacol. Exp. Ther.327 : 538–545.
Storelli, F., Desmeules, J., and Daali, Y. (2019). Genotype-sensitive reversible and time-dependent CYP2D6 inhibition in human liver microsomes. Basic Clin. Pharmacol. Toxicol. 124 : 170–180.
Tay-Sontheimer, J., Shireman, L.M., Beyer, R.P., Senn, T., Witten, D., Pearce, R.E., et al. (2014). Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics. Pharmacogenomics 15 : 1947–1962.
Thomas, A., Hopfgartner, G., Giroud, C., and Staub, C. (2009). Quantitative and qualitative profiling of endocannabinoids in human plasma using a triple quadrupole linear ion trap mass spectrometer with liquid chromatography. Rapid Commun. Mass Spectrom. RCM 23 : 629–638.
Villaseñor, A., Ramamoorthy, A., Silva dos Santos, M., Lorenzo, M.P., Laje, G., Zarate, C., et al. (2014). A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response-related difference in mitochondrial networks. Br. J. Pharmacol. 171 : 2230–2242.
Wake, D.T., Ilbawi, N., Dunnenberger, H.M., and Hulick, P.J. (2019). Pharmacogenomics: Prescribing Precisely. Med. Clin. North Am.103 : 977–990.
Whiley, L., Chekmeneva, E., Berry, D.J., Jiménez, B., Yuen, A.H.Y., Salam, A., et al. (2019). Systematic Isolation and Structure Elucidation of Urinary Metabolites Optimized for the Analytical-Scale Molecular Profiling Laboratory. Anal. Chem. 91 : 8873–8882.
Xia, J., and Wishart, D.S. (2011). Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst. Nat. Protoc. 6 : 743–760.
Yeung, P.K. (2018). Metabolomics and Biomarkers for Drug Discovery. Metabolites 8 : 11.
Zhang, H., Basit, A., Wolford, C., Chen, K.-F., Gaedigk, A., Lin, Y.S., et al. (2020). Normalized Testosterone Glucuronide as a Potential Urinary Biomarker for Highly Variable UGT2B17 in Children 7–18 Years. Clin. Pharmacol. Ther. 107 : 1149–1158.